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Cyclic-AMP (cAMP)-dependent protein kinase (PKA) is the main effector of cAMP
signaling in all tissues. Inactivating mutations of the PRKAR1A gene, coding for the type
1A regulatory subunit of PKA, are responsible for Carney complex and primary pigmented
nodular adrenocortical disease (PPNAD). PRKAR1A inactivation and PKA dysregulation
have been implicated in various types of adrenocortical pathologies associated with
ACTH-independent Cushing syndrome (AICS) from PPNAD to adrenocortical adenomas
and cancer, and other forms of bilateral adrenocortical hyperplasias (BAH). More recently,
mutations of PRKACA, the gene coding for the catalytic subunit C alpha (Cα), were
also identified in the pathogenesis of adrenocortical tumors. PRKACA copy number gain
was found in the germline of several patients with cortisol-producing BAH, whereas the
somatic Leu206Arg (c.617A>C) recurrent PRKACA mutation was found in as many as
half of all adrenocortical adenomas associated with AICS. In vitro analysis demonstrated
that this mutation led to constitutive Cα activity, unregulated by its main partners, the
PKA regulatory subunits. In this review, we summarize the current understanding of the
involvement of PRKACA in adrenocortical tumorigenesis, and our understanding of PKA’s
role in adrenocortical lesions. We also discuss potential therapeutic advances that can
be made through targeting of PRKACA and the PKA pathway.
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Introduction
The adrenal cortex is divided into three concentric zones: the outermost zone named zona
glomerulosa, the centrally located zona fasciculata and the innermost, zona reticularis involved in
the production of mineralocorticoids, glucocorticoids, and androgens, respectively (Blake et al.,
2008; Mcnicol, 2013). Thus, adrenal dysfunction leads to several hormonal syndromes due to the
hypo- or hyper-secretion of one or more adrenal hormones.
In this review, we focus on Cushing’s syndrome (CS) resulting from overproduction of cortisol
from adrenocortical tumors (ACT). CS leads to central obesity and metabolic abnormalities
and several other manifestations including moon face, buffalo hump, striae, and opportunistic
infections (Newell-Price et al., 2006). Severe and prolonged hypercortisolism could lead to
increased morbidity and mortality, due to sepsis, cardiovascular, and other complications (Plotz
et al., 1952; Arnaldi et al., 2012). Hypersecretion of cortisol can be due to either an excess of
pituitary or ectopic adrenocorticotropin hormone (ACTH) secretion or adrenocortical tumors
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(ACT) secreting cortisol autonomously; the latter form of CS is
known as “ACTH-independent CS” (AICS).
Cortisol-producing ACTs include bilateral adrenocortical
hyperplasias (BAH), adrenocortical adenomas (ACA) and
cancer (ACC). BAHs account for 10–15% of AICS and are
classified in two subtypes: macronodular (nodules >1 cm)
and micronodular (nodules <1 cm) (Lacroix, 2009; Duan
et al., 2014). Macronodular hyperplasia, previously known
as massive macronodular adrenocortical disease (MMAD) or
ACTH-independent macronodular adrenocortical hyperplasia
(AIMAH), has been recently renamed as primary macronodular
hyperplasia (PMAH) after the discovery of intra-adrenal ACTH
production (Lacroix, 2013; Louiset et al., 2013). PMAH is
typically diagnosed in the fifth and sixth decade of life; subclinical
CS is common in this disease (Duan et al., 2014), despite the fact
that macroscopically, the adrenal glands are massively enlarged
with a combined weight reach from 60 to 200 g.
Micronodular hyperplasias include a pigmented form named
primary pigmented nodular adrenocortical disease (PPNAD),
which is typically diagnosed at a younger age. PPNAD is the
most common endocrine lesion of Carney complex (CNC),
occurring in more than 60% of CNC patients (Almeida and
Stratakis, 2010). Grossly, PPNAD is associated with normal to
slightly enlarged adrenal glands (4.3–17 g) with a large number
of yellow to brown-black micro-nodules (0.1–0.3mm in size) due
to lipofuscin accumulation (responsible for the pigmentation)
(Stratakis and Boikos, 2007; Stratakis, 2008).
Unilateral ACTs, ACAs account for 90% of adrenal CS
(Newell-Price et al., 2006; Bertagna et al., 2009). Clinically, these
tumors arise at any age, with a slight female predominance.
The presentation ranges from subclinical to overt CS.
Macroscopically, the average ACA ranges in size from 1.5 cm to
6 cm and weighs between 10 and 40 g. In contrast to ACAs, ACCs
are rare and account for few cases of adrenal CS (Wajchenberg
et al., 2000). They arise sporadically, mostly around the fourth
and fifth decade of life; ACCs typically weigh more than 100 g,
tend to be adherent to other tissues, or invade adjacent structures.
cAMP Signaling, PRKAR1A Defects, and
Adrenocortical Tumors
In normal physiology, cAMP signaling plays an essential role
in the regulation of cortisol secretion under the control of the
hypothalamic-pituitary-adrenal axis (Figure 1). Hypothalamic
corticotropin-releasing hormone (CRH) secretion stimulates
ACTH secretion from the pituitary gland, both acting through
their respective G-protein coupled receptor (GPCR). ACTH
binds to the melanocortin-2 receptor (MC2R) in zona fasciculata
cells, leading to the activation of adenylate cyclase, which
ensures the conversion of adenosine triphosphate (ATP) to cyclic
adenosine monophosphate (cAMP). cAMP activates its main
intracellular mediators, EPAC (Exchange Protein Activated by
cAMP), and a serine/threonine kinase called cAMP-dependent
protein kinase A (PKA) (Bossis and Stratakis, 2004). The protein
kinase A (PKA) holoenzyme is a heterotetramer that consists of
two regulatory subunits each binding to one catalytic subunit
(Bossis and Stratakis, 2004). Four regulatory (RIα, RIβ, RIIα, and
RIIβ) and four catalytic (Cα, Cβ, Cγ, and Prkx) subunits have
been described (Almeida and Stratakis, 2011). In order to activate
PKA cAMP interacts with the regulatory subunit of PKA leading
to a conformational change permitting the release of the catalytic
subunits. The free catalytic subunits phosphorylate downstream
targets such as cAMP response element-binding protein (CREB),
which induce the transcription of target genes, such as those
involved in cortisol synthesis (Figure 1) (Christenson et al., 1999;
Manna et al., 2009). The intracellular cAMP is hydrolysed by
specific phosphodiesterases (PDEs), and the two regulatory and
catalytic subunits of PKA are reassembled in order to return to
their inactive state (Stratakis and Boikos, 2007).
Several lines of evidence support cAMP’s role in the
development of cortisol-producing ACTs (Stratakis, 2014a).
In McCune-Albright syndrome (MAS), which is caused by
mutations in theGNAS gene that encodes the stimulatory subunit
α of the G protein (Weinstein et al., 1991), ACAs or, more
frequently, BAH are common. In CNC, inactivating mutations
of the PRKAR1A gene (encoding the RIα subunit of PKA)
(Kirschner et al., 2000a,b) lead to PPNAD. Mutations of the
PRKAR1A gene have also been identified in sporadic cases of
PPNAD (not associated with CNC), as well as in ACAs (Groussin
et al., 2002; Bertherat et al., 2003). In addition, a number
of in vitro and transgenic mouse studies have demonstrated
that PRKAR1A is an adrenocortical tumor suppressor gene and
its inactivation leads to ACTH-independent cortisol secretion
(Sahut-Barnola et al., 2010; Almeida and Stratakis, 2011).
PRKACA Genetic Defects Lead to Tumors
of the Adrenal Cortex
In an initial cohort of 10 cortisol-producing ACAs
associated with overt AICS, the Leu206Arg (c.617A>C)
PRKACA recurrent mutation was identified in 70% of
these cases; with one ACA having another PRKACA defect,
Leu199_Cys200insTrp (Beuschlein et al., 2014). Both of
these mutations affect residues that are highly conserved
across species from invertebrates to humans suggesting the
major role played by these amino acids is in protein function
(Beuschlein et al., 2014; Goh et al., 2014). Dalmazi and
collaborators have also identified two additional mutations:
the insertion Cys200_Gly201insVal (c.600_601insGTG)
and the missense Ser213Arg (c.639C>G) associated with
12 base pair duplication Leu212_Lys214insIleIleLeuArg
(c.638_640insATTATCCTGAGG), in respectively 13.4% (3/22)
and 4.5% (1/22) of their cortisol-producing ACA cohort (Di
Dalmazi et al., 2014b). Recently, four independent projects of
exome sequencing of cortisol-producing ACA development
(Cao et al., 2014; Goh et al., 2014; Kubota et al., 2014; Sato et al.,
2014) led to confirmation of PRKACA’s role in the pathogenesis
of this neoplasm. The Leu206Arg variant has been identified at a
frequency that ranges from 14.2 to 65.5% of cortisol-producing
ACA depending on the studies (Beuschlein et al., 2014; Cao
et al., 2014; Di Dalmazi et al., 2014a; Goh et al., 2014; Nakajima
et al., 2014; Sato et al., 2014). No PRKACAmutations were found
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FIGURE 1 | cAMP signaling. (A) In normal adrenocortical cells, ACTH
binds to its G-coupled receptor, MC2R. This leads to the activation of
adenylate cyclase (AC), which convert ATP into cAMP. cAMP then binds the
regulatory (R) subunit of PKA, inducing the release of the catalytic subunit
(C). The catalytic subunit phosphorylates its downstream target such as
CREB, which in turn induces the expression of genes involved in cortisol
synthesis. (B) In adrenocortical adenoma cells producing cortisol
autonomously with PRKACA mutations (star), the catalytic (C) subunit of PKA
is unable to interact with the regulatory subunit (R). The unregulated PRKACA
may now mediate its serine-threonine kinase activity without any restrains.
either in 1600 in-house exomes or in the 1000 Genomes Project
data set or in blood of patients harboring PRKACA mutations
in tumors. The Leu206Arg substitution likely alters the function
of the Cα subunit at the heterozygote state, since both the wild
type and mutant alleles were expressed in the tumor tissue
(Beuschlein et al., 2014; Goh et al., 2014).
Functional Analysis of PRKACA Mutations
PRKACA encodes the most highly expressed catalytic PKA
isoform in the human adrenal and the functional consequences
of two mutant variants have been predicted using different
modeling approaches based on mouse PKA crystal structure
(Beuschlein et al., 2014; Cao et al., 2014; Goh et al., 2014;
Sato et al., 2014). In the absence of cAMP, the regulatory
subunit fits into a highly conserved hydrophobic cleft in the
catalytic subunit formed by Leu206 and Leu199. Therefore,
the substitution from the small hydrophobic leucine to a large
positively charge hydrophilic arginine in position 206 should
abolish the interaction between the catalytic and regulatory
subunit leading then to cAMP-independent PKA activation
(Figure 1) (Beuschlein et al., 2014; Cao et al., 2014; Goh et al.,
2014; Sato et al., 2014). Similar consequences are predicted for
each one of the pathogenic PRKACA variants that have been
identified so far in ACAs (Di Dalmazi et al., 2014a).
The activating effect of the novel PRKACAmutations in ACA
predicted by what is known about the structural biology of
the PKA tetramer has been validated by in vitro experiments
in HEK293 cells for the most frequent variant, Leu206Arg
(Beuschlein et al., 2014; Cao et al., 2014; Goh et al., 2014; Sato
et al., 2014). The expression of Leu206Arg PRKACA increases the
PKA activity and the level of CREB phosphorylation at Ser133
in basal conditions compared to the wild type PRKACA in two
independent studies; the Leu206Arg did not interfere with the
catalytic activity (Beuschlein et al., 2014; Cao et al., 2014; Goh
et al., 2014). In contrast with cells transfected with the wild-type
sequence, the Leu206Arg is not responsive to cAMP stimulation
and its activity is not reduced by the co-expression with excess
wild-type regulatory subunit (Beuschlein et al., 2014). The
absence of interaction between this variant and the regulatory
subunit was confirmed by FRET and co-immunoprecipitation
experiments (Beuschlein et al., 2014; Goh et al., 2014; Sato et al.,
2014). Altogether, these results demonstrated that the Leu206Arg
mutant protein is constitutively active. Consistent with these
conclusions, basal PKA activity in ACA with PRKACAmutations
compared to those without mutations is increased (Beuschlein
et al., 2014; Cao et al., 2014). Similarly, Goh and collaborators
demonstrated by immunohistochemistry a higher staining of
the phosphorylation of CREB at Ser133 in 8 PRKACA mutant
ACA vs. 5 ACA without identified mutations (Goh et al., 2014).
However, Sato and collaborators did not find any differences in
phosphorylation level of CREB byWestern blot (Sato et al., 2014).
Clinical Phenotype Associated with PRKACA
Mutations
In total, the PRKACA gene has now been sequenced in 854 ACTs
and no mutations have been found in cortisol-producing ACCs,
non-secreting ACAs, androgen-secreting ACAs, aldosterone-
producing ACAs, and adrenal oncocytomas. Thus, the overall
frequency of the PRKACA hotspot mutation is 38.2% and it has
been identified in cortisol-producing adenomas only (Table 1).
One study described a predominance of PRKACA mutations
in females (Cao et al., 2014). Patients harboring tumors with
PRKACA mutations were diagnosed with CS at younger ages
(45.3 ± 13.5 vs. 52.5 ± 11.9 years) (Goh et al., 2014). In five
studies including both overt and subclinical CS (Beuschlein et al.,
2014; Di Dalmazi et al., 2014b; Goh et al., 2014; Nakajima et al.,
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2014; Sato et al., 2014), PRKACA mutations are significantly
associated with overt CS and higher serum cortisol level after
1mg of dexamethasone, increased urinary free cortisol and
midnight cortisol levels compared to patients without mutations
(Beuschlein et al., 2014). These results highlight a direct link
between PRKACA mutations and cortisol production, which
is expected knowing the physiological function of PKA. In
accordance with this observation, no PRKACA mutations have
been found in subclinical CS patients in three independent
studies (Beuschlein et al., 2014; Di Dalmazi et al., 2014b;
Nakajima et al., 2014). However, Gao et al. and Sato et al.
have found 11% (3/27) and 22% (2/9) of PRKACA mutations,
respectively, at position 206 in subclinical CS patients (Table 1)
(Goh et al., 2014; Sato et al., 2014). The term subclinical CS is
used to describe cortisol-secreting tumors in patients without any
typical symptoms of CS. However, its usage can vary between
investigators and countries; this may explain the differences
observed between these studies. Interestingly, in transcriptomic
data from 25 wild-type ACA and 11 mutant ACA, 232 genes
are differentially expressed and pathway analysis demonstrates
an enrichment in “biosynthesis and metabolism of steroid and
cholesterol” and “response to chemical stimulus” (Cao et al.,
2014). This is in accordance with the essential role of PKA in the
control of cortisol secretion.
PRKACA and other Defects in ACAs
Altogether these results demonstrate that PRKACA mutations
constitutively activate PKA leading to cortisol-producing
adenomas, thereby suggesting that PRKACA is a main
contributor to adrenocortical tumorigenesis. By whole-exome
sequencing analysis, even if the number of exonic mutations
is generally low, PRKACA is not the only oncogene mutated
in cortisol-producing tumors. Activating mutations have also
been identified in CTNNB1 and GNAS genes at lower frequency
(Cao et al., 2014; Goh et al., 2014; Sato et al., 2014). Importantly,
PRKACA mutations were never found in association with other
mutations. This suggests that the identified activating mutations
may be mutually exclusive confirming the driver role played by
Cα subunits in the development of cortisol-producing ACA.
Interestingly, Goh and collaborators sequenced both ACA and
ACC and were able to divide the ACA into two groups based
on genetic results (Goh et al., 2014). Five out of 22 ACA are
genetically closer to 3 ACC even if their Weiss score is 0 or 1,
without any histological evidence of carcinoma. These findings
are consistent with a progressive model of tumors forming in the
adrenal cortex in the sequence hyperplasia-adenoma-carcinoma
(Berthon et al., 2010; Stratakis, 2014b). However, the second
ACA group, which included the ACA with PRKACA mutations,
appears to have a distinct tumorigenesis mechanism. This
is supported by the observation of three studies that tumors
with mutations in PRKACA were significantly smaller than the
non-mutant ones (Di Dalmazi et al., 2014b; Goh et al., 2014; Sato
et al., 2014). Similarly, the weight of the sporadic ACT harboring
PRKAR1A mutations is lower (11.2 ± 0.8 vs. 23.4 ± 12.05 g)
(Bertherat et al., 2003). Therefore, PKA activation through
constitutive activation of Cα subunit or RIα loss-of-function
drastically increases cortisol secretion but has a limited impact
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 May 2015 | Volume 3 | Article 26
Berthon et al. PRKACA: a main contributor in adrenocortical tumorigenesis
on cell proliferation and tumor growth. Most recently, genomic
duplication of the locus of PRKACB encoding for the Cβ catalytic
subunit have also been described in a patient with CNC without
CS (Forlino et al., 2014). It is possible that this reflects different
roles of the two main catalytic subunits of PKA, with regards to
their function in the adrenal cortex.
PRKACA Copy Number Gain and Bilateral
Adrenocortical Hyperplasia
Comparative genomic hybridization of 35 BAH with overt
CS demonstrated copy number gain at chr19p locus that
included PRKACA gene in 5 patients (Beuschlein et al., 2014;
Stratakis, 2014a; Carney et al., 2015). The defect was present
in the germline and there were no PRKACA coding sequence
mutations. Two patients, a mother and a son, included in
this study the same duplication and both presented with BAH
(Beuschlein et al., 2014; Carney et al., 2015); this is the only
case of inheritance in the cohort. Other duplications at this
locus have not been found in 24 cortisol-producing ACAs
(Carney et al., 2015). Interestingly, the histological phenotype
of these five patients has been published and 3 of them
looked like PPNAD. This phenotype is comparable with PKA
activation through PRKAR1A inactivation or PDEs mutations
causing PPNAD (Almeida and Stratakis, 2010). However, the
two remaining patients did not have PPNAD but diffuse
adrenal cortex hyperplasia with nodules (Carney et al., 2015).
This demonstrates that the same genetic alteration can lead
to different histological phenotypes. It also demonstrates that
differences in PRKACA gains and, thus, functional “dosage”
have different effects on the histology of the adrenal cortex
(Stratakis, 2014a). Whereas somatic mutations that lead to
overactivity cause ACAs (Stratakis, 2014a), germline defects
cause BAH depending on genetic dosage (Lodish et al.,
2015).
Is Cα a new Therapeutic Target for Cushing
Syndrome?
PRKACA mutations have been described in almost 40% of
cortisol-producing ACA and are therefore, the most frequent
genetic alteration in these tumors (Table 1). Beyond the
importance of PKA in adrenal, its involvement in genetic diseases
like CNC and cancers has been demonstrated (Caretta and
Mucignat-Caretta, 2011). The ability to inhibit its constitutive
activation through chemical components is a major challenge
due to its critical role on cell function. Two inhibitors H89 and
KT5720 have successfully decreased PKA activity induced by the
transfection of Leu206Arg variant in HEK293 cells (Sato et al.,
2014). These two inhibitors have been extensively used to better
understand the role of PKA, however, their lack of specificity
has been well established (Lochner and Moolman, 2006; Murray,
2008). Most of the inhibitors targeted the ATP-binding site but
this was problematic due to the high percentage of identity
of this domain among the Ser/Thr kinases family responsible
to the low specificity of these inhibitors (Sapio et al., 2014).
Moreover, these inhibitors cannot be used for activating PRKACA
mutations. Better understanding of PKA function permits the
development of substrate-competitive inhibitors, which would
be more specific as there is diverse substrate-binding domain.
The PKA inhibitor (PKI) is an endogenous thermostable peptide
that interacts with the catalytic domain and is able to inhibit
Leu206Arg variant in vitro (Cao et al., 2014). However, its
main disadvantage preventing its use for clinical application
is its weak permeability and its susceptibility to proteases.
The discovery of new PKA inhibitors is desirable and can be
helpful in the treatment of cortisol-producing ACA but also
others cancers.
Conclusions
The discovery of somatic mutations in PRKACA is one additional
proof of the central role of cAMP-PKA pathway in the
development of cortisol-producing ACA. The high frequency of
mutations (approximately 40%) and the even higher presence
of PKA function alterations (Bimpaki et al., 2009), suggest that
perhaps other components of the pathway may also be found
mutated in the future. However, as PRKACA is ubiquitously
expressed, its mutations may also be found in other tissues with
PKA-dependent tumorigenesis. Future analysis and use of animal
models will provide useful information to help answer this, and
other, questions.
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